MaxCyte (LON:MXCT) Sets New 12-Month Low – Here’s What Happened

by · The Cerbat Gem

MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 177 ($2.33) and last traded at GBX 202.77 ($2.67), with a volume of 418041 shares traded. The stock had previously closed at GBX 192 ($2.53).

MaxCyte Trading Up 5.6 %

The company has a market capitalization of £267.66 million, a PE ratio of -7.43 and a beta of 1.13. The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81. The business has a fifty day moving average price of GBX 258.95 and a 200 day moving average price of GBX 294.59.

About MaxCyte

(Get Free Report)

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.

Featured Articles